Welcome to our dedicated page for Moringa Acquisition news (Ticker: MACAU), a resource for investors and traders seeking the latest updates and insights on Moringa Acquisition stock.
Moringa Acquisition Corp (MACAU) is a blank check company focused on effecting a merger or business combination with Israel-related technology companies. Recently, Moringa announced a proposed merger with Silexion Ltd, an oncology-focused biotechnology company. Silexion's product, Loder™, has shown promising results in a Phase 2a clinical trial for non-resectable pancreatic cancer. The business combination is expected to close in the third quarter of 2024, subject to customary closing conditions and regulatory approvals.
Moringa Acquisition Corp (NASDAQ: MACA) announced the adjournment of its Extraordinary Meeting, initially scheduled for February 7, 2023, to February 9, 2023. This meeting aims to vote on extending the deadline for completing a business combination from February 19, 2023, to August 19, 2023. Shareholders are advised to participate and review the Definitive Proxy Statement filed with the SEC. The company previously entered into a business combination agreement with Holisto Ltd., a tech-powered travel agency. The record date for shareholders to vote remains January 3, 2023.
On June 13, 2022, Holisto Ltd and Moringa Acquisition Corp (Nasdaq: MACA) announced a merger agreement, enabling Holisto to become publicly listed. The combination values Holisto at approximately $405 million and provides non-redeeming Moringa shareholders with a bonus of up to 1,725,000 shares. Holisto, leveraging AI technology, aims to disrupt the $194 billion online hotel booking market with personalized offerings. The transaction is expected to close in Q4 2022, subject to shareholder and Nasdaq approvals.
Moringa Acquisition Corp (NasdaqCM: MACA, MACAU, MACAW) filed its annual report on Form 10-K for the year ended December 31, 2021, with the SEC on March 31, 2022. This report is accessible through their official website and the SEC's site. The company targets mergers and acquisitions, particularly focusing on technology firms related to Israel. The press release also includes a reminder that forward-looking statements are based on management's beliefs and assumptions, and actual results may differ due to various factors.
Moringa Acquisition Corp has announced the pricing of its initial public offering (IPO) at $10.00 per unit, totaling 10,000,000 units. The units will be listed on Nasdaq under the symbol 'MACAU' starting February 17, 2021. Each unit includes one Class A ordinary share and one-half of a redeemable warrant, allowing the purchase of additional shares at $11.50. The Company aims to focus on Israel-related technology firms and has engaged EarlyBirdCapital, Inc. and Moelis & Company as joint book-running managers. A registration statement was approved by the SEC on February 16, 2021.